Diabetes Mellitus and the Heart

Katharina Schütt; Dirk Müller-Wieland; Nikolaus Marx

doi:10.1055/a-1018-9065

Experimental and Clinical Endocrinology & Diabetes, Table of Contents

Exp Clin Endocrinol Diabetes 2019; 127(S 01): S102-S104
DOI: 10.1055/a-1018-9065

German Diabetes Association: Clinical Practice Guidelines

Diabetes Mellitus and the Heart

Authors

Katharina Schütt

¹Medical Clinic I - Cardiology, Angiology and Internal Intensive Care Medicine, RWTH Aachen University Hospital, Aachen, Germany
Dirk Müller-Wieland

¹Medical Clinic I - Cardiology, Angiology and Internal Intensive Care Medicine, RWTH Aachen University Hospital, Aachen, Germany
Nikolaus Marx

¹Medical Clinic I - Cardiology, Angiology and Internal Intensive Care Medicine, RWTH Aachen University Hospital, Aachen, Germany

Abstract

Full Text

References

References
1 Di Angelantonio E, Kaptoge S, Emerging Risk Factors C. et al. Association of cardiometabolic multimorbidity with mortality. JAMA 2015; 314: 52-60. doi:10.1001/jama.2015.7008
2 Consentino FF, Grant PJ, Aboyans V. et al. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2019; 2019
3 Zinman B, Wanner C, Lachin JM. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. The New England Journal of Medicine 2015; 373. doi: 10.1056/NEJMoa1504720
4 Neal B, Perkovic V, Mahaffey KW. et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017;
5 Wiviott SD, Raz I, Bonaca MP. et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2018; 380: 347-357
6 Marso SP, Daniels GH, Brown-Frandsen K. et al. Liraglutide and cardio- vascular outcomes in type 2 diabetes. N Engl J Med 2016; 375: 311-322. doi: 10.1056/NEJMoa1603827
7 Marso SP, Bain SC, Consoli A. et al. Semaglutide and cardiovascular out- comes in patients with type 2 diabetes. N Engl J Med 2016;
8 Nichols GA, Gullion CM, Koro CE. et al. The incidence of congestive heart failure in type 2 diabetes: An update. Diabetes Care 2004; 27: 1879-1884
9 MacDonald MR, Petrie MC, Varyani F. et al. Impact of diabetes on out- comes in patients with low and preserved ejection fraction heart failure: An analysis of the candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM) programme. Eur Heart J 2008; 29: 1377-1385
10 Ponikowski P, Voors AA, Anker SD. et al. 2016 ESC Guidelines for the di- agnosis and treatment of acute and chronic heart failure: The task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special con- tribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016; 18: 891-975. doi: 10.1002/ejhf.592
11 Kirchhof P, Benussi S, Kotecha D. et al. ESC Guidelines for the ma- nagement of atrial fibrillation developed in collaboration with EACTS: The task force for the management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC Endorsed by the European Stroke Organisation (ESO). Eur Heart J 2016; 2016